117 MET ECD shedding and poor DFS 40. Yang Y, Mandiyan S, Robinson BS, McMahon G. Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors. Cancer Res 2016;76:5788-97. 41. Doshi S, Ray D, Stein K, Zhang J, Koduru P, Fogt F, et al. Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer. Diagnostics (Basel) 2016;6. 4
RkJQdWJsaXNoZXIy MTk4NDMw